Evidence map›Paper›PMID 38673870›Full record

ArticleInternational journal of molecular sciences2024

Lipidomics Analysis Unravels Aberrant Lipid Species and Pathways Induced by Zinc Oxide Nanoparticles in Kidney Cells.

Boyun Kim, Gaeun Kim, Hyun Pyo Jeon, Jewon Jung

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Boyun KimDepartment of SmartBio, College of Life and Health Science, Kyungsung University, Busan 48434, Republic of Korea.ORCID 0000-0002-4973-6647
Gaeun KimDepartment of SmartBio, College of Life and Health Science, Kyungsung University, Busan 48434, Republic of Korea.
Hyun Pyo JeonDepartment of SmartBio, College of Life and Health Science, Kyungsung University, Busan 48434, Republic of Korea.
Jewon JungDepartment of SmartBio, College of Life and Health Science, Kyungsung University, Busan 48434, Republic of Korea.
Kyungsung University · KR

Funding

Korea Basic Science Institute 2021R1A6C103A387National Research Foundation of Korea 2021R1F1A1050105the Chemical safety management specialist training program (2021) funded by Korea Chemicals Management Association (KCMA) N.A.
6 · The paper itself

Abstract

Zinc oxide nanoparticles (ZnO NPs) are widely used in versatile applications, from high technology to household products. While numerous studies have examined the toxic gene profile of ZnO NPs across various tissues, the specific lipid species associated with adverse effects and potential biomarkers remain elusive. In this study, we conducted a liquid chromatography-mass spectrometry based lipidomics analysis to uncover potential lipid biomarkers in human kidney cells following treatment with ZnO NPs. Furthermore, we employed lipid pathway enrichment analysis (LIPEA) to elucidate altered lipid-related signaling pathways. Our results demonstrate that ZnO NPs induce cytotoxicity in renal epithelial cells and modulate lipid species; we identified 64 lipids with a fold change (FC) > 2 and

Indexed as

KidneyLipid MetabolismLipidomicsZinc OxideBiomarkersCell LineEpithelial CellsHumansLipidsMetal NanoparticlesSignal TransductionBiomarkersLipidsZinc Oxideceramidekidneylipidlipidomicsnanotoxicitysphingolipidzinc oxide nanoparticles

Identifiers

PMID38673870
PMCPMC11050686
OpenAlexW4394767623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.